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ABSTRACT 
Cancer is a dreadful disease and, in most cases, leads to death even when it is being treated. Even though synthetic drugs are still in use for the 
treatment of cancer, the seriousness of the side effects of these drugs has boggled researcher’s mind to find more effective drugs which will help to 
overcome the side effects and have greater potency in trying to make the patient completely free of the disease. Recently, researchers turned their 
attention towards bio-components present in natural products. Curcumin, a polyphenol and the main constituent of a rhizome Curcuma longa, has 
geared significant interest due to its wide spectrum of therapeutics values, especially anticancer activity. Paper summarizes the chemistry and bio-
metabolism of curcumin in the human body. Aim of this review article is to gather the dispersed efforts of researchers predominantly in improving 
the bioavailability of curcumin. In the present review, comprehensive literature on anticancer activity of Curcumin via combination therapy, 
structure modification, synthesis of analogues, novel delivery systems have been highlighted. Besides, the review paper explicated several 
challenges associated with Curcumin as an adjuvant chemotherapeutic agent and emphasizes more on clinical studies. 
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INTRODUCTION 
Worldwide, cancer has become the second most lethal disease. In 
2018, it has been reported that in the US alone, about 1.73 million 
new cases and more than 609,000 deaths occurred due to cancer [1]. 
Although there is a noticeable advancement in medical science and 
technology for cancer therapy, there is no decline in new cases and 
the rate of mortality in the same disease for the past few decades [2].  
Normal body cells are governed by signalling pathways which give 
instructions according to the requirement and work in an orderly 
process. They divide when the body requires new cells while the old 
and damaged cells die on their own accord. In cancer, abnormal 
multiplication of cells happens [3]. 
Due to some triggering reaction inside or outside, the cells start 
dividing and re-dividing continuously even when the body does not 
require it. Also, the old cells do not die but survive and start dividing 
like the normal cells. These undifferentiated cells form a lump like 
structure called a tumour. Most cancers form solid tumours, but 
cancers of connective tissue are in the liquid state, for example, 
leukemia or blood cancer [3–6]. 
Mainly, tumours are of two types: Malignant and Benign. Benign 
tumours do not move out from their place of origin but grow to exert 
pressure on the surrounding body parts but do not invade other tissues 
or parts of the body. Such tumours can be removed by surgery and the 
patient becomes completely free from the disease as it does not recur. 
Malignant tumours, also known as cancerous cells, break open and 
invade the surrounding tissues. They can enter the bloodstream or the 
lymph and travel to other parts of the body, where it gets attached 
somewhere and starts dividing. This is called metastasis [6-7] (fig. 1). 
Treatment for metastasized cancer becomes difficult as multiple 
treatments are required without the guaranty of complete cure, as 
there is always a possibility of recurrence [7]. In case of a normal 
healthy cell, it carries out all its functions in a programmed way, 
which is controlled by the genes which regulate the enzymes, 
hormones and proteins. All the signals sent by the genes reach the 
spot as per the requirement of cells. But cancerous cells can evade 
these signals and develop their system. A cancerous cell could 
develop its blood vessels parallel to the normal blood vessels of the 
body and use them for its growth [8, 9] (fig. 1). 
Similarly, cancer cells can override the immune system, which under 
normal conditions protect the healthy normal cells, disrupt the other 
functions of the cells or utilize the immune system for their benefit, thus 
saving themselves from destruction (fig. 1). So, if any change occurs in 
the genes, it gives rise to the malfunctioning of the body, leading to cause 
cancer. Thus, cancer can be termed as a genetic disease. Not all genetic 
changes cause cancer but genetic changes that bring about mutations of 
Deoxyribonucleic acid (DNA) may lead to cancer [3, 7, 9]. 
There are different types of cancer. Based on the place of origin, they 
can be grouped into 3 categories: (1) Carcinoma-cancer of epithelial 
cells (2) Sarcoma-cancer of connective tissue and (3) Leukemia or 
liquid tumour, which mainly arises from blood-forming cells and 
lymphomas that arise from cells of the immune system [10].  
There are some characteristic features of cancer cells which help 
them to survive. These pro-survival traits of cancer cells have some 
unique features, such as cancer cell, when divide, they never 
differentiate as normal cell; cancer cells lack normal signalling 
responses, nuclei of cancer cells are abnormal and larger than the 
normal cell which is also asymmetric. They also have changes in the 
chromatin, abnormalities to structures called mitotic spindle that 
assist in cell division and various genetic abnormalities like a 
mutation in gene sequencing. Cancer cells utilize glucose 5 or 10 
times more than the normal cells for their energy instead of oxygen 
production. They can also be called as “metabolite parasite” because 
they steal energy from the host. Mitochondria with mutated genes as 
well as the changed protein structures and enzymes, are present in 
the cancer cell. Cancer cells can form new blood vessels which help 
in delivering oxygen and nutrients to the cancer cell. This is done by 
sending out chemical signals that promote angiogenesis [10]. 
Thus, for the prevention and treatment of this deadly disease, 
understanding of molecular alterations and progression are the key 
factor. Treatment for this disease depends on the type of cancer, 
stage of the disease and the age of the body. Many treatments are 
available to treat the disease but the commonly used (conventional 
methods) are surgery, radiation therapy and chemotherapy. If 
cancer has not metastasized, then removal of the infected tumour is 
done by surgery and patients can be completely cured [11]. 
Radiation therapy is mostly used in combination with other 
therapies where high energy gamma rays or X-rays are made to fall 
on the cancerous part, which shrinks or destroys the cancer cells. It 
makes the patient completely free from the disease and increases 
the survival rate [12]. Chemotherapy is a mode of introducing 
chemicals (drugs) into the body to kill the cancerous cells. Drugs 
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may be synthetic, semi-synthetic or natural. This mode of therapy 
can be advised at all stages of the disease, but this is specifically 
advised when the cancer cells have metastasized as these chemicals 
can travel throughout the body [13, 14]. Both radiati
chemotherapy have serious side effects. Radiation damages the 
healthy cells surrounding the cancerous tissue, which may or may not 
recover at all. Chemotherapeutic drugs can also cause nausea, hair fall, 
fatigue, and vomiting [12–14]. Thus, considering noxious side effects, 
deadly off-target effects and ineffective expressions are prevalent 
phenomena for most of the current therapeutic protocols. Recently 
with the advancement of technology, various modern techniques have 
been developed like immunotherapy, hormone therapy, gene therapy 
etc. In immunotherapy, chemicals are introduced, which triggers the 
immune system of the body and the body becomes self
fight the disease and restore the body to normalcy. In local 
immunotherapy, only the affected area will be administered by agents
  
 
The goal of gene therapy is to replace the damaged genes with the new 
one that works to address the cause of cancer. Gene
focus on further damaging cancer cell DNA to the point where the cell 
commits suicide. If genes responsible for cancer are altered or replaced 
in DNA, the cells start functioning normally [18–21].
These modern therapies are still in the nascent stage yet to receive 
success. Researchers are trying to find out alternative 
drugs/treatments, which will be more efficient, cost
less or no side effects and helpful in increasing the survival rate. 
Researchers adopted many strategies by targeting explicit cancer 
cells, to impede or to control the growth, progress and metastasis of 
tumors without causing severe side effects [22].
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while systemic immunotherapy treats the whole body [15, 16]. 
Immunotherapy can be considered targeted if the treatment 
specifically tells the immune system to destroy the cancer cells and it 
can be considered non-specific if it improves the cancer
abilities by stimulating the immune system. Several types of cancer are 
linked to some types of hormones
prostate cancer (testosterone). Hormone therapy is designed to
change the hormone production in the body to stop the growth of 
cancer cells or to kill them completely. Cell activities are governed by 
hormones secreted by the cell itself. Similarly, the cancerous cell also 
secretes hormones which help in the prolifera
secretions of these hormones are altered, they can bring about cell 
death. For example, Tamoxifen drug, given to breast cancer patients
helps in reducing the production of oestrogen hormone, thereby 
inducing cell death. Similarly, prostate cancer can be treated by 
reducing testosterone hormone levels [17].
Fig. 1: Six hallmarks of cancer [3] 




One such process used for the treatment is a combination of drugs 
which are being used in monotherapy. Different combination of drugs 
was being experimented to overcome the resistance for the single drug 
by cancer cells or for the synergistic effect of the
the effect of the main drug towards the disease. 
more drugs were used in combination to find their synergistic effect in 
arresting proliferation or apoptosis of cancer cells.
Combination of Dabrafenib and Tramet
proto-oncogene B-Raf and v-Raf murine sarcoma viral oncogene 
homolog B (BRAF) inhibitor and MEK [acronym MEK derives from 
Mitogen-activated protein kinase
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 drugs or to enhance 
In this method, two or 
  
inib, which were used as 
/extracellular-signal-regulated 
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tested to find out whether it could delay the resistance of the drugs 
in the treatment of metastatic melanoma. The experiments showed a 
delay in resistance, which improved the survival rate of patients 
with metastatic melanoma due to mutation of BRAF V600E or 
V600K [23]. Authors concluded that this combination is successful, 
provided the side effects are properly addressed [23, 24]. 
Laboratory synthesized small molecule drugs in combination with 
anticancer drugs were tested for its efficacy and efficiency on the 
treatment of breast cancer using Michigan Cancer Foundation-7 
(MCF-7) cell lines. Anticancer drugs, 5-Fluorouracil (5-FU), 
Oxaliplatin and Taxol was used in combination with two synthetic α-
methylene-δ-lactones with chroman-2-one skeleton and compared 
with Parthenolide, a plant-derived α-methylene-γ-lactone, which 
was considered as the positive control. The results showed that the 
combination of α-methylene-δ-lactones with chroman-2-one 
skeleton with 5-FU and Oxaliplatin showed a synergistic effect in 
MCF cells [25]. Various other combination of drugs was tried, like a 
combination of Trastuzumab, Paclitaxel, Carboplatin and their 
results were compared with the combination of Trastuzumab and 
Paclitaxel to treat women having a protein called human epidermal 
growth factor receptor 2 (HER-2) overexpressing Metastatic Breast 
Cancer. The response was good, and survival increased with the 
introduction of Carboplatin to the combined drugs Paclitaxel and 
Trastuzumab [26]. 
Administering drugs orally or intravenous faced some drawbacks 
such as the drug may not reach the target site or even if it reaches 
dose may not be sufficient. Metabolism or loss of some amount is 
possible before reaching the target site. Thus, to make the drug more 
effective scientist explored many drug delivery tools in the form of 
nanoparticles, hydrogel system, nanotubes, metal complex, 
coordination polymer etc.  
Nano coordination polymer particles loaded with Oxaliplatin and 
Gemcitabine were used to find the synergistic effect on Human 
pancreas adenocarcinoma cell line (AsPc-1) and human pancreatic 
cancer cell line (BxPc-3) cancer cell lines. Results revealed that the 
therapeutic effects of drugs increase many folds rather than when 
drugs were given individually or in combination without using any 
delivery system [27]. 
Gemcitabine and Cis-platinum were co-delivered using a 
biodegradable thermosensitive hydrogel system in the treatment of 
pancreatic cancer. Authors noted a strong synergistic effect of the 
drugs on the pancreatic cancer cell line Bxpc-3 with reduced side 
effects [28].  
In a review paper, authors mentioned different combination strategies 
like chemotherapeutic combination, nucleic acid-based co-delivery, 
intrinsic sensitive and extrinsic stimulus combinational patterns, and 
combination therapy involving nanomaterials as drug delivery system. 
They concluded that nanomedicine-based combination anticancer 
therapy could be employed for the synergistic activity in cancer 
treatment, which synergistically improved anti-cancer outcomes. 
There are certain challenges to be faced in the combination therapy of 
nucleic acids and small drug molecules like drug resistance by the 
cancer cells, the difference in the pathways of the drug action, ratio of 
the drug combination etc. [29, 30]. 
All the above-mentioned methods of drug delivery have some 
drawbacks like multidrug resistance, differences in modes of action 
of drugs etc. So, progress in research led the researchers to turn 
towards natural products as they have been used as home remedies 
i.e. first aid treatments for various diseases. This has opened the 
doors for products found in nature to be used as drugs for the 
treatment [31].  
Many natural products are being used as traditional medicines in 
branches of medicine like Ayurveda, Unani, Homeopathy [32-34] etc. 
Natural products are finding prime importance along with allopathic 
medications for their easy availability, lesser side effects, and 
synergistic effects. Plants and herbs have been used traditionally 
since ancient times as home remedies for simple ailments like the 
common cold, diarrhoea, inflammation, small burns, or cuts etc. [35]. 
They are rich in bio-components, responsible for the special activity 
like antioxidant, anti-inflammatory, antibacterial, antimalarial, 
antimutagenic, anticancer etc. A lot of research work has been 
carried out on secondary metabolites of plant and herbs like 
polyphenols, flavonoids, terpenoids, saponins and brassinosteroids. 
Scholars explored their effects and efficiency for several therapeutic 
values. Phyto components have shown very promising results with 
less toxicity [31, 35]. Many secondary metabolites of plants have 
been identified and studied for their anti-cancer activity, antioxidant 
activity, inhibition of cancer cell growth, induction of apoptosis, 
target specificity, cancer cell cytotoxicity etc. [35].  
Silver nanoparticles prepared using Bauhinia variegata have shown 
antibacterial activity against some strains of bacteria like Bacillus 
subtilis, Escherichia coli, Pseudomonas aeruginosa and Staphylococcus 
aureus [36]. Silver nanoparticles prepared from the bark of Ficus 
krishnae have been tested for antibacterial and anticancer activity 
which have a great affiance against them [37]. Gymnemic acid 
extracted from Gymnema sylvester has shown interesting biological 
profile with low cyto-permeability [38].  
By green synthesis approach, the synthesis of silver nanoparticles 
was carried out by using leaf extract of Psidium guajava. Prepared 
silver nanoparticles were encapsulated with a biopolymer i.e. 
dextran sulphate as a stabilizing agent. Cytotoxicity of the prepared 
silver nanoparticles was investigated against MCF-7 cell line. By 
exhibiting 91% of cell inhibition, prepared dextran sulphate 
stabilized green silver nanoparticles have shown potent anticancer 
activity against MCF-7 cell line [39]. 
Extracts from turmeric, ginger and garlic were studied for their 
activity against breast cancer cell lines MCF-7, Human Caucasian 
breast carcinoma (ZR-75) and M. D. Anderson-Metastasis Breast 
cancer-231 (MDA-MB 231). Authors noted that plant extract had 
radical scavenging property and led to apoptosis in all the cell lines 
namely MCF-7, ZR-75, and MDA-MB 231 [40]. Numerous anticancer 
combinations with different approaches have been utilized from 
herbs and plants sources, such as Catharanthus roseus, Taxus 
brevifolia, Betula alba, Erythroxylum pervillei, Cephalotaxus species,  
Curcuma longa and many others [41]. 
To amass the depth information on Curcuma longa, literature survey 
(1964-2020) was done from peer-reviewed research articles from 
globally reputed journals such as Science Direct, Mendeley, Royal 
Society of Chemistry, Springer link, PubMed Central (PMC), 
Multidisciplinary Digital Publishing Institute (MDPI), search libraries 
of World Health Organization (WHO), National Library of Medicine 
(NLM), Council for Scientist and Industrial Research (CSIR), 
Shodhganga, etc. Used keywords were mainly curcumin, anticancer 
activity, drug delivery, nanoparticles, and bioavailability. To write 
this article, predominantly used search criteria was the 
combination/formulation of curcumin to enhance its anticancer 
activity. From years as traditional medicine, different curcuma 
species are well documented for several therapeutic activities. In the 
present review article, to understand the action mechanism of 
Curcumin, its chemistry, degradation and metabolism have been 
summarised. Furthermore, to increase the bioavailability of 
curcumin, this review article discussed the several strategies and 
emerging technologies opted by scholars. 
Of all the medicinal plants, Curcumin, an important phytochemical of 
herb Curcuma longa of the ginger family, has been of great interest. 
In 1870, Curcumin was extracted from Curcuma longa (turmeric 
plant) for the first time in the crystalline state [42, 43]. Multi bio-
functionality properties of Curcumin and its derivatives have 
received enormous attention by the researchers such as anti-
bacterial, antimalarial, antimutagenic, anti-tumor, antioxidant, anti-
inflammatory activities etc. [44]. Most of the properties are 
endorsed due to the presence of key elements in the chemical 
structure of Curcumin [45]. 
Thus, a lot of scientific work has been done on Curcumin and its 
derivatives. To improve the biological and physicochemical 
properties of Curcumin, numerous research work shed light on the 
Structure-activity relationship (SAR) of different key functional 
groups present in Curcumin. In quest of treating cancer with more 
efficacy by using anticancer agents of less toxicity and fewer side 
effects, this review has primarily engrossed on the Curcumin and its 
anticancer activity. Authors reported that Curcumin is capable to 
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suppress numerous cellular signalling pathways which supports its 
anticancer activity [46]. Curcumin is capable to target several cancer 
cell lines including breast cancer cell lines, lung cancer cell lines, 
prostate cancer cell lines, brain tumours and head and neck 
squamous cell carcinoma [47]. 
Although Curcumin, a golden spice, exhibited multidimensional 
therapeutic advantages, it has certain limitations which hinder its 
broad-spectrum applications like poor water solubility, stumpy 
chemical stability, low oral bioavailability, and less cellular uptake 
[48, 49]. Hydrophobic nature of Curcumin makes its molecule to 
breach into the cell membrane and bind up with fatty acyl chains of 
cell membrane lipids via hydrophobic interactions and hydrogen 
bonding. This causes less accessibility of Curcumin in the cytoplasm. 
Hence, to overcome all these issues and to make Curcumin more 
effective and selective towards cancer cells, several strategies are 
suggested and explored by the researchers. Among them, structural 
modifications in Curcumin, synthesis of Curcumin analogues, use of 
Curcumin in combination therapy, different delivery systems for 
delivery of Curcumin alone or with other drugs etc. are few 
approaches. The present review focuses on recent literature on the 
chemistry of Curcumin, Curcumin in combination therapy and novel 
ways of delivery systems that have been experimented by authors 
for cancer therapy. 
Curcuma species 
Curcuma species are herbaceous plants with thick, fleshy rhizomes, 
pseudo stems and leaf blades have flower spikes that arise from the 
top of the pseudostem or sometimes on a separate stem directly 
from the rhizome. The inner part of rhizomes come in different 
colours, like white, cream, yellow, orange, blue, bluish-green, and 
black [50]. 
Rhizomes of this plant are widely used as flavouring preservative 
and colouring agent. The main bioactive constituent extracted from 
this rhizome is Curcumin, which is responsible for the therapeutic 
property of turmeric. A wide range of Curcuma species had been 
explored for different activities in several extracts obtained from 
different solvents, which are listed in table 1. 
 
Table 1: Curcuma species and their activities 
Name of species Solvent extract Bioactivity Reference 
Curcuma aeruginosa Aqueous extract Antioxidant,  
Anti-inflammation 
[51] Wan-Ibrahim et al., 
[52] Angel et al. 
Curcuma amanda Aqueous extract Antioxidant, 
Anti-inflammatory 
[53] Venugopalan et al., 
[52] Angel et al. 
Curcuma aromatia Aqueous extract Antioxidant, 
Anti-inflammatory 
[54] Lee et al., 
[52] Angel et al. 
Curcuma brog Aqueous extract.  Anti-inflammation  [52] Angel et al. 
Curcuma caesia Aqueous extract,  
Enzymic and crude extract 
Anti-inflammation,  
Antioxidant 
[52] Angel et al., 
[55] Dhal et al. 
Curcuma comosa Aqueous extract Antioxidant [56] Boonmee et al. 
Curucma domestica Aqueous extract Antioxidant [57] Saputri and Jantan 
Curcuma haritha Aqueous extract Antioxidant [58] Rajan et al. 
Curcuma kwangsiensis Essential oils Antifungal [59] Zhang et al. 
Curcuma longa Aqueous extract, 
Benzene extract, 














[61] Manda et al.,  
[62] Dinesha et al.,  
[63] Ramadas and Srinivas, 
[64] Chandrasekaran et al.,  
[65] Madan et al., 
[66] Mohankumar and McFarlane, 
[67] Azuine et al., 
[68] Jin et al., 
[69] Zhang et al., 
[70] Rafatullah et al., 
[71] Chander H, 
[72] Prakash et al., 
[73] Idris et al., 
[74] Jacob and Toloue, 
[75] Yan et al. 
Curcuma malabarica Aqueous extract Anti-inflammation  [52] Angel et al. 
Curcuma manga Aqueous extract, 
Methyl alcohol extract 
Antioxidant 
 
[51] Wan-Ibrahim et al., 
[76] Chan et al. 
Curcuma mutabilis Aqueous extract Anti-oxidant [58] Rajan et al. 
Curcuma neilgherrensis Aqueous extract Anti-oxidant [58] Rajan et al. 
Curcuma ochrorhiza Hexane extract.  Cytotoxicity [77] Sukari et al. 
Curcuma phaeocaulis Ethyl alcohol extract Antifungal [78] Li et al. 
Curcuma rakthakanta Aqueous extract  Anti-inflammation [52] Angel et al. 
Curcuma sylvatica Aqueous extract Anti-inflammation [52] Angel et al. 
Curcuma vamana Aqueous extract Antioxidant [58] Rajan et al. 
Curcuma viridiflora Methyl alcohol extract Antioxidant [79] Chen et al. 
Curcuma wenyujin Ethyl alcohol extract  Antioxidant [80] Lou et al. 
Curcuma xanthorrhiza Aqueous extract, 
Methyl alcohol extract 
Anti-oxidant 
 
[81] Qader et al., 
[57] Saputri and Jantan 
Curcuma zedoaria Aqueous extract, 
Methyl alcohol extract  
Anti-inflammation 
Anti-oxidant 
[82] Ullah et al., 
[83] Hong et al., 
[79] Chen et al. 
Radix curcumae The plant Gastric protective [84] Lu et al. 
In another review, Arnab Sen presented the anticancer activity of some curcuma species, which is listed in table 2 [85].  
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Table 2: Anti-cancer activities of different curcuma species 
Name of species Name of tested cell line Conclusion Reference/s 
Curcuma Amanda Roxb. 
(Common name-mango  
ginger) 
Anti-cancer activity on lung cancer cell line 
H460 of the 60 cells lines from National 
Cancer Institute (NCIH460) and adenoca 
DNA rcinomic human alveolar basal 
epithelial cells (A-549) is reported to be due 
to the presence of compounds  
like difurocumenonol and amadaldehyde  
Herb acts through AKT (AK mice strain  
Transforming capabilities) also known 
as Protein kinase B (PKB) signalling 
pathway 
[86] Policegoudra RS 
et al., 







Sesquiterpenoids β-element, Germacrone 
and Curcumin derivatives are present in 
Curcuma  
aromatica which showed Inhibition of  
human colon carcinoma cell (LS-174-T) 
anti-proliferation was observed.  
 
It involves in induction of apoptosis via 
down regulation of cyclin B1 and Cyclin-
dependent kinase 1 (CDK1) and without 
the participation of p53. C. aromatica oil 
was also found to exhibit 
antiproliferative effect on human  
hepatocellular carcinoma Hepa1-6  
cells  
[88] Bing H et al., 





Antitumor activity of this herb was tested 
on three human-cancer cell  
lines-(MCF-7) human breast cancer, human 
colon cancer cell line (HCT-116) and 
ovarian Cancer cell line. 
Anti-cancer activity was shown to be 
active through the tumour necrosis 
factor alpha (TNF α) mediated nuclear 
factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) signalling 
pathway 
[90] Shaikh A M et al. 
Curcuma  
longa Common  
name-Turmeric) 
 Curcuma longa have shown anti- 
tumour effect on human colon carcinoma 
cells lines (HCT116, SW480, CaCo2, HT29, 
and SW837). n-Hexane extract is more 
effective on human lung cancer cell line 
(A549). Curcuma C20-di-aldehyde which 
was isolated from this rhizome was able to 
supress the proliferation of HCT116, HT29 
and Henrietta Lacks (HeLa cells). 
Curcuma longa shows inhibition of 
telomerase activity in a dose-dependent  
manner 
[91] Mohammad P  
et al. 
Curcuma mangga Herb has been reported to inhibit tumour 
growth in (MCF-7), Human Colorectal 
Adenocarcinoma (HT-29), prostate cancer 
(PC-3) cell lines 
Curcuma mangga induces early and  
late apoptosis and arrested the  
cells at the G0/G1 phase.  





This herb induces apoptosis in (HT-29) 
human Colorectal denocarcinoma cells. 
Different extracts have shown  different 
activity. 
Induction is through activating the 
mitochondrial death pathway via 
the Protein family/associated X 
protein/B-cell lymphoma -extra large 
(Bcl-2/Bax/Bcl-xl) and  
reactive oxygen species (ROS)  
production. Inhibitory effect 
may also be due to augmentation of  
COX-2 expression levels by other 
constituents of the rhizome 
[93] Rouhollahi E et 
al., 
[94] Hong S et al. 
Curcuma xanthorrhiza  
(Common name–Temu Lawak) 
Antiproliferative activities were found 
by this herb on MDA-MB-231, MDA-MB-453,  
Memorial Sloan–Kettering Cancer Center  
(SK-BR-3), MCF-7, YMB-1 and T47D 
different breast cancer cell lines 
Antitumor effect  was due to 
Bisabolane Sesquiterpenoids, α-
Curcumin, ar-turmerone and 
Xanthorrhizol.  
[95]Oon SF et al. 
Curcuma zedoaria  
(Common name  
-white turmeric) 
This herb shows specificity towards human 
oesophageal cancer cells (TE-8). 
 
It induces apoptosis through caspase  
cascade dependent pathways, which  
involved activation of caspase-9, 
caspase-3 and Poly (ADP-ribose) 
polymerases (PARP) along with 
suppression of Bcl-2 through the 
intracellular signaling pathway 
(Akt/mTOR).  
[96] Seo W et al., 
[97]Pal P et al. 
 
Study of the above tables indicates that of all the given species of 
Curcuma, Curcuma longa shows a broad spectrum of therapeutics as 
well as anti-cancer activity on several cell lines.  
Curcuma longa Linnaeus (common name-turmeric) belongs to 
Plantae kingdom of Magnoliophyta division in zingiberaceous order 
(Family: Zingiberaceae, genus: Curcuma and species: longa) 
[98]. Curcuma longa is used as a medicine for nearly 4000 
y. Curcuma longa is a principal spice in Asian kitchens in the form of 
a yellow powder colouring agent [99]. The rhizome of Curcuma 
longa is rich in several bioactive components (fig. 2). Curcumin is the 
main bioactive component of Curcuma longa. A wide range of 
therapeutic properties of Curcuma longa is mainly due to Curcumin 
from cough-cold to cancer treatment [100]. Curcumin, a polyphenol, 
is seeking the attention of researchers, especially in the field of 
pharmacy, medicine and in chemistry. 
It has also been seen that Curcumin can modulate many molecular 
targets, which are the causes for the onset of many diseases in the 
human body (fig. 3) [101]. 
 - 
 
Chemistry of curcumin 
Curcumin is known as diferuloylmethane and its chemical formula is 
C21H20O6 with molecular weight 368.38. IUPAC name of Curcumin is 
1, 7-bis (4-hydroxy-3-methoxyphenyl) hepta-1, 6
In Curcumin, three chemical entities-and α, β
diketone moiety and two aromatic rings with o
groups are present. Both aromatic ring with o
groups are connected via α, β-unsaturated β-diketone moiety 
linker with 7 carbon atoms [102-104].  
Diketo group of the Curcumin exhibited keto
Depending on the environment, keto-enol tautomerism (
4b) can exist in different conformers. In non-polar and in moderately 
polar solvents, enol form is more stable than keto form. In crystal 
state, Curcumin stays in cis-enol configuration. In solution, Curcumin 
exists as cis-trans isomers where transform (when both phenolic
methoxy groups are on the opposite sides) is somewhat more stable 
than the cis-form (where both phenolic-methoxy groups are on the 








Fig. 4 (a): Structure of curcumin
 
Depending on the geological conditions where Curcumin had been 
grown, it contains 2-9% of Curcuminoids. Curcuminoids are the group of 
compounds like Curcumin, Demethoxycurcumin (DMC) and 
Bisdemethoxycurcumin (BDMC) (fig. 5). All three compounds are almost 
the same structurally except that Desmethoxycurcumin, 
Bisdemethoxycurcumin is devoid of methoxy groups which are present 
in Curcumin. Bisdemethoxycurcumin and desmethoxycurcumin also 
show anti-cancer activity [103, 105]. 
Jyotsna et al. 
Int J App Pharm, Vol 12, Issue 5, 2020, 
 
Fig. 2: Flowers and rhizomes of curcuma longa 
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Various strategies were tried by the research scholars to extract and 
to synthesize Curcumin and its derivatives in the laboratory. S. J 
Kulkarni gave a detailed procedure for the extraction and 
purification of Curcuminoids from the rhizome of herb Curcuma 
longa. According to them, Soxhlet extraction is the ideal method 
using methanol solvent to get high yields [106].  
 
 
Fig. 6: Schematic presentation for the synthesis of curcumin [107] 
 
H. J. J Pabon synthesized Curcumin in the laboratory by using vanillin, 
acetylacetone and boric anhydride as catalyst (fig. 6). It was finally 
concluded that by changing catalyst such as tri-isopropyl borate and 
tri-sec: Butyl borate, the yield of Curcumin increases [107]. 
Wehrli and Christof synthesized Curcumin using boric acid, vanillin, 
m-xylene, acetylacetone, dimethylformamide and benzylamine 
under different reaction time to increase the yield of Curcumin from 
54% for heating for 2 h to 83% for heating for 3 ½ h. In one method, 
from this reaction mixture, Curcumin was isolated using acetic acid 
and purified by refluxing with methanol. The final yield was 69%. In 
another method, ethyl acetate and acetic acid were used to extract 
Curcumin from the reaction mixture and crystallized using methanol 
with a final yield of 59%. Another route of synthesis was tried by 
replacing benzylamine with 1-butyl amine and changing the 
pressure and temperature parameters compared to the first route. 
Here, the yield was 68%. In still another route, 1-butylamine was 
replaced with 2-ethoxymethyl amine and changing the reaction 
parameters like pressure, temperature etc. obtained the yield of 
71% [108]. Lincy Joseph et al. synthesized the Curcumin and 
confirmed the structure of Curcumin by Nuclear Magnetic 
Resonance (NMR) result. They obtained orange coloured needle-
shaped crystals and characterized by NMR, Infra-Red (IR) and Mass 
spectral analysis [109].  
Thus, different authors experimented with various ways to optimize 
the yield of Curcumin by using numerous reagents and by altering 
the conditions of the reaction. Researchers tried to find the cause of 
low bioavailability of Curcumin. They studied the metabolism of 
Curcumin, trying to find out what happens when Curcumin enters 
the human body. Manfred Metzler et al. reviewed the metabolism of 
Curcumin [110]. They discussed about the poor systemic 
bioavailability of Curcumin. In their paper, they mentioned that even 
after the administration of large doses of Curcumin, their 
concentrations were not detectable in the plasma or blood or urine. 
Takanori Tsuda et al. summed up the metabolite products of 
Curcumin. Here, it is mentioned that when Curcumin homogenates 
with a microsome fraction of human intestinal and liver tissue, the 
major metabolite is Curcumin glucuronide. When Curcumin was 
incubated with cytosol fraction, it produces Curcumin sulfate and 
Hexahydrocurcumin with a minor portion of Tetrahydrocurcumin 




Fig. 7: Degradation pathways of curcumin (cleavage and oxidation) [111] 
 
These reactions suggest that due to the low solubility of Curcumin, 
its absorption by the body is very less and before Curcumin reaches 
the target site, it gets metabolised. To overcome these problems, 
many synthetic and experimental changes (mainly in vitro) were 
carried out by scholars and they were successful up to some extent 
[111]. 
Majority of them tried the different mode of delivery and 
synthesized the analogues of Curcumin. Various nanoparticles of 
Curcumin like polymer nanoparticles, liposomes, micelles, Solid 
Lipid Nanoparticles (SLNs) and polymer conjugates have been 
developed to deliver the drug to the target site. Shengfeng Peng et al. 
prepared Curcumin nanoparticles by pH driven method at various 
concentrations of biosurfactant and sophorolipid solution. Alkaline 
Curcumin and acidic sophorolipid solutions were stirred constantly. 
After incubation of a period, Curcumin nanoparticles were 
centrifuged. Curcumin nanoparticles were then tested for their 
bioavailability in different phases. It has been observed that 
Curcumin becomes soluble in a basic medium and gets a negative 
charge. Under acidic conditions, Curcumin loses its negative charge 
and its solubility decreases. This makes it to enter the core of 
surfactant micelles, which leads to the formation of sophorolipid 
coated Curcumin nanoparticles increasing the bioavailability of 
Curcumin [112]. 
To overcome the limitation of oral Curcumin administration, Suryani 
et al. prepared Curcumin nanoparticles and formulated them into 
transdermal patches. Results revealed that with an average weight 
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of 0.7 g, patches contain moisture content from 1.0 to 6.0%. Tensile 
strength of developed Curcumin nanoparticles transdermal patches 
was found to be 1.0 to 2.0 N/mm. The authors concluded that 
developed Curcumin nanoparticles transdermal patches 
demonstrated good flux values for the penetration of Curcumin 
nanoparticles into the skin [113]. 
Mahesh Kharat et al. investigated the physical and chemical stability 
of Curcumin in oil in water emulsion at different pH levels, which 
indicated that Curcumin emulsions are stable in acidic pH and 
yellow colour faded in alkaline medium. Thus, it was concluded that 
emulsion-based delivery systems would be better for the chemical 
stability and aqueous dispersibility of Curcumin [114]. Review 
article of Mohammad N. Oskouie et al. discussed a novel way for 
Curcumin delivery. Curcumin was introduced into the human body 
by two different methods via encapsulation and primed method 
using exosomes. In the Curcumin-encapsulated method, the drug is 
loaded onto the exosomes while in the Curcumin-primed method, 
cells are treated with Curcumin and then Curcumin-exosome is 




Fig. 8: Metabolism of curcumin (conjugation and reduction) [111] 
 
 
Fig. 9: Delivery of curcumin using exosomes for anticancer activity [115] 
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Sauraj et al. developed Xylan-Curcumin pro-drug, which was self-
assembled into nanoparticles for the delivery of Curcumin. It was found 
to be highly pH-sensitive and releases most of the drug at a lower pH. It 
demonstrated a higher toxicity than Curcumin [116]. Sreeraj Gopi et al. 
developed liposomal Curcumin powder (LCP) based on nanofiber 
weaving technology (NFW technology) which increases the 
bioavailability and stability of Curcumin. Curcumin could be protected 
from rapid metabolism and reach the target site (fig. 10) [117]. 
 
 
Fig. 10: Preparation of phospholipid vesicle for the delivery of curcuminoids [117] 
 
Sujit et al. review paper discussed the Nanocochleates as an oral 
potential for the delivery of anticancer drugs which can be used as 
an alternate for delivering the therapeutic or biological agents to 
cancer cells. In the paper, authors exemplified the various methods 
to prepare Nanocochleates and mechanisms of drug delivery. In the 
end, author/s recommended that in the treatment of cancer cells, 
application of Nanocochleate can progress the effectiveness of 
chemotherapeutic agents and this novel drug delivery system can 
push the therapeutic world into the renewed era [118]. 
Other than different delivery modes, researchers experimented with 
other options to increase the solubility and bioavailability of Curcumin 
by synthesising novel compounds. In these experiments, synthetically, 
they tried to attach various groups to the parent Curcumin and termed 
as Curcumin derivatives of Curcumin analogue. With the advancement of 
technology, before synthesizing them, their suitability can be confirmed 
by a computational tool like molecular docking.  
Manouchehr Teymouri et al. evaluated the biological and 
pharmacological properties of Dimethoxy Curcumin (DiMC) as a stable 
Curcumin analogue. DiMC, a synthetic analogue of Curcumin exhibited 
superior anti-cancer activity and metabolic stability. DiMC lack phenolic-
OH groups as opposed to Curcumin. DiMC exerts unique molecular 
activities compared to Curcumin, including induction of androgen 
receptor (AR) degradation and suppression of the transcription factor 
activator protein-1 (AP-1). Authors concluded that enhanced AR 
degradation on DiMC treatment suggests it as a novel anticancer agent 
against resistant tumours with androgenic etiology [119]. 
Govindharasu Banuppriya et al. synthesized water-soluble Curcumin 
derivatives containing amine. Synthesized Curcumin derivatives showed 
cytotoxicity against HeLa cell lines. By immunoblot analysis, it was 
evidenced that there is induced p53 mediated apoptosis. The compound 
also showed a good binding property with the DNA of the cell [120]. 
Papers reported that Octahydrocurcumin (OHC), the final hydrogenated 
metabolite of Curcumin has potential biological activities. Zhenbiao 
Zhang et al. demonstrated that the anti-tumour activity of OHC was more 
pronounced than Curcumin. OHC upregulated the p53 expression and 
down-regulated murine double minute 2 homolog (T) expression. Also, 
it reduced Bcl-2 and Bcl-xl protein expressions. In ascitic cells, Bax and 
Bad expressions were increased by OHC. This suggested that 
hydrogenation of the C7 linker double bonds and the carbonyl groups 
might afford more potent anti-hepatocellular carcinoma (anti-HCC 
effect) by upregulating p53 expression and downregulating murine 
double minute 2 expression [121]. 
Shivakumar S. Jalde et al. synthesized series of Chlorine-6-Curcumin (C-
6-cur) conjugates and tested for their photosensitizing potential against 
pancreatic cancer cell lines. They confirmed that above compound 
showed excellent photodynamic therapy (PDT) efficacy with inhibitory 
concentration 50 (IC50) of 40, 35 and 41 nano Molar (nM) AsPC-1, MIA 
PaCa-2 and PANC-1 respectively. This compound upregulated the 
expression of BAX, cytochrome-C and cleaved caspase 9 while 
downregulating the Bcl-2 expression, an anti-apoptotic protein marker. 
This compound has the potential to trigger the intrinsic apoptotic 
pathway in AsPC-1 a pancreatic cancer cell line [122]. 
Mahin Ramezani et al. mentioned that BDMC, a natural analogue, present 
in the rhizome Curcuma longa along with Curcumin, also possess anti-
tumour activity. This compound has shown more effective anticancer 
activity than Curcumin in almost all type of cancers through different 
pathways [123]. Apoptotic effect of BDMC is induced by reducing the 
levels of heme oxygenase-1, BCL-2 (an anti-apoptotic protein). BDMC 
increases the level of ROS. Through mechanistic evaluations, the pro-
apoptotic effect is interfered by binding to cannabinoid receptor-2 and 
there is an activation of downstream effectors like the Fas-dependent 
death pathway, caspase-8, and caspase-3 [123]. On the same line to 
increase the effectiveness of Curcumin, scientists tried numerous 
approaches such as combination therapy. Curcumin is used in the mode 
of combination therapy with other synthetic, semi-synthetic and natural 
products along with other mono-therapeutic drugs. In this practice, 
Curcumin was found to act synergistically and resulting in enhancing the 
effect of the mono-therapeutic drug. Nano form of Curcumin in 
combination with synthetic drugs like Cisplatin loaded onto liposomes 
were tried on hepatic cancer HA22T/VGH cell line both individually and 
combined. Studies revealed that combination therapy increases the 
intracellular ROS level, retention time and dramatically improved the 
anti-tumour effect [124].  
Curcumin combined with Erlotinib, Sunitinib and Sorafenib along 
with Doxorubicin was tested in vitro and in vivo for their synergistic 
effects for anti-cancer activity. Among all combinations, Curcumin 
with Sunitinib displayed the maximum potency. Remaining 
combinations also presented a better effect than when they had 
Jyotsna et al. 
Int J App Pharm, Vol 12, Issue 5, 2020, 70-84 
79 
been administrated alone [125]. Curcumin and Metformin were 
combined and tested for its anti-proliferative activity against breast 
cancer cells of mice. The combination treatment unveiled the highest 
effects against tumour proliferation and growth. It significantly 
reduced vascular endothelial growth factor (VEGF) expression, 
induced Tryptophan 53 (Trp53) independent apoptosis, triggered 
Th2 (T Helper Cell Type 2) immune response and showed no toxicity 
[126]. Docetaxel is the most used chemotherapeutic agent to target 
androgen signalling in metastatic prostate cancer (PCa). However, 
prolonged treatment with Docetaxel results in drug-resistant cancer 
cells. Curcumin is a non-toxic organic compound with multifaceted 
chemopreventive potential. The human prostate cancer cell lines-
PCa cell lines, DU145 and PC3 were treated with Curcumin and 
Docetaxel alone and in their different combinations. Authors 
reported that treatment using a combination of Curcumin and 
Docetaxel inhibited the proliferation and induced apoptosis 
significantly higher than the Curcumin and Docetaxel-treated group 
alone. Interestingly, the combined treatment with Curcumin and 
Docetaxel modulates the expression of Receptor Tyrosine Kinases 
(RTKs), Phosphoinositide 3-kinase (PI3K), PKB, also known as Akt, 
which is a serine/threonine-specific protein kinase (phospho-AKT), 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
kappa B), p53, and cyclooxygenase-2 (COX-2). This shows that 
combination therapy is a boon for cancer patients through complete 
success is yet very far to be reached [127]. 
Thus, combination therapy sets a new pathway for treading along the 
success path and inspire the scientists to put more efforts on natural 
products, either alone or in combination to increase their bioavailability 
and efficiency at the target site. In this series, Huarong Huang et al. tested 
combination of α-Tomatine, a glycoalkaloid (phytochemical in tomatoes) 
and Curcumin on different prostate cancer cells. In results, they stated 
that combinations of α-tomatine and Curcumin synergistically inhibited 
the growth and induced apoptosis in prostate cancer PC-3 cells. Effects of 
the α-tomatine and Curcumin combination were associated with 
synergistic inhibition of NF-κB activity and a potent decrease in the 
expression of its downstream gene Bcl-2 in the cells [128].  
Quercetin, a natural bio-active compound and Curcumin were 
applied separately and in combination to human gastric carcinoma 
cell line (MGC-803) cells by Zhang J. et al. Combined treatment with 
Curcumin and Quercetin resulted in significant inhibition of cell 
proliferation, accompanied by loss of mitochondrial membrane 
potential, the release of cytochrome c and decreased 
phosphorylation of AKT and ERK. Results indicated that the 
combination of Curcumin and Quercetin induces apoptosis through 
the mitochondrial pathway [129]. 
Ergul Mutlu Altunda et al. investigated the combination of Quercetin 
and Curcumin on Chronic Myeloid Leukaemia (K562) Cells. They 
confirmed that less dose of combined formulation is effective to 
induce apoptosis via through mitochondrial pathway. It increases 
the ROS levels and decreases the Glutathione (GSH) levels. Results of 
messenger Ribonucleic acid (mRNA) and protein expression 
suggested that probably cytochrome-c was released from 
mitochondria, which caused PARP and caspase-9 cleavages [130].  
Two compounds Ellagic acid (a polyphenol found in raspberries, 
walnuts, strawberries) and Curcumin was tested on HeLa cell lines by 
Ergul Mutlu Altunda et al. and it showed better activity synergistically 
than individually [130]. Curcumin and extracellular matrix in different 
combinations were studied for their anti-proliferative activity on MCF-
7 (breast cancer cell lines) and found that extracellular matrix proteins 
boosted the activity of Curcumin [131]. 
Natural extracts from turmeric, ginger and garlic were tested for 
their anti-cancer activity against all breast cancer cell lines. The 
bioactive constituents of these natural extracts without Tamoxifen 
(a synthetic drug commonly used for breast cancer) induces 
apoptosis. With Tamoxifen, these extracts showed greater anti-
cancer activity than when Tamoxifen was given alone. Authors 
suggested that there is a possibility that natural extracts may be 
sensitizing the cancer cells towards Tamoxifen [132].  
Though Curcumin and Resveratrol are promising anti-cancer drugs, 
their low bioavailability and low solubility hinder their therapeutic 
use. But with an advanced drug delivery system, this drawback could 
be overcome to a certain extent. This has opened the doors for 
further exploration [133]. 
Curcumin and Mannan from Aloe vera have shown inhibition of the 
proliferative activity of immune cells like peripheral blood 
mononuclear cells (PBMC) or monocytes in the human body. So, these 
can be used for alternative or complementary medicines quite 
effectively [134]. In case of colorectal cancer, Curcumin enhanced 5-FU 
expression of proapoptotic proteins (caspase-8,-9,-3, PARP, and BAX) 
and simultaneously, it downregulated antiapoptotically (Bcl-xL) and 
proliferative (cyclin D1) proteins leading to cell death. So, when 
combined with 5-FU, it mediates apoptosis of resistant cells. Adjuvant 
chemotherapy with Curcumin and combination of drugs Folinic acid, 
Fluorouracil and Oxaliplatin (FOLFOX) has been quite successful in the 
treatment of gastric cancer. Wnt1 gene expression has been shown to 
decrease in the case of child leukemia patients. Similarly, adjuvant 
chemotherapy of Curcumin with Doxorubicin or Cisplatin induces cell 
cycle arrest by initiating the intrinsic apoptotic pathway. Curcumin has 
been found to be a suitable adjuvant in the treatment of other cancers 
like cervical and oral cancer as well as sensitizing cancer stem cells, 
thereby reducing their population [134]. 
Review article of Abir Kumar Panda et al. explains the mechanism of 
Curcumin to arrest the growth of cancer cells (fig. 11) [135]. Curcumin 
inhibits ABC transporter function, cell cycle progression, apoptosis, 
angiogenesis, the expression of anti-apoptotic proteins, multiple cell 
survival signaling pathways and their cross-communication, and by 
modulating immune responses. It also induces the initiation of both 
p53-dependent and p53-independent G2/M phase cell cycle arrest. So, 
Curcumin can be used either alone or in the form of combination 
therapy for treating different cancers [135]. 
 
 
Fig. 11: Cellular pathways affected by curcumin in the treatment of cancer [135] 
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In different research studies, it has been specified that Curcumin can 
constrain the interleukin-6 (IL-6)-mediated phosphorylation of 
Signal transducer and activator of transcription 3 (STAT3) and adept 
to downregulate the NF-κB, thus the proliferation of cancer cells can 
be subdued by using Curcumin [136-137]. In the treatment of 
colorectal cancer cells, Curcumin downregulated the miR-21 gene, 
which is overexpressed. Curcumin inhibited the activator protein 
(AP-1) binding to promoter i.e. miR-21 [101]. In the case of HCT 116 
colorectal cancer cells, there will be cell cycle arrest in the G/M 
phase via miR-21 gene regulation. Thus, Curcumin again helps to 
inhibit the tissue growth of the tumour [138]. 
In an in vivo study of colorectal cancer, the better response was 
noticed towards radiation therapy after it combined with Curcumin. 
Author elucidate that it might be due to the ability of Curcumins to 
target NF-κB [139]. Further research proves that Curcumin in both 
cases i.e. in vitro and in vivo is capable to induce apoptosis and 
inhibit proliferation of prostate cancer [140]. Unambiguously, this is 
done by meddling with various cellular pathways like nuclear factor 
κ (NFκB), epidermal growth factor receptor (EGFR), and (MAPK) 
[141-142]. A recent study has discovered that Curcumin is proficient 
to activate protein kinase D1 (PKD1), which leads to the dilution of 
oncogenic signalling by MAPK and β-catenin consequently reticence 
of prostate cancer [143]. In numerous head and neck carcinomas, 
particularly STAT3 and NF-κB were found to be overexpressed. In 
vitro studies of Curcumin in different head and neck cancer cell lines 
have proven to be very positive. Since Curcumin can affect many 
cellular pathways involved in cell proliferation, it can adequately 
inhibit cell growth [144]. 
Combating with brain tumors take diverse cellular pathways, like 
autophagy, apoptosis, invasion, metastasis and angiogenesis and 
pervading the blood-brain barrier (BBB) is a major limitation. Neil V. 
Klinger and Sandeep Mittal have found that Curcumin can arrest 
G2/M cell cycle arrest in a dose-dependent manner [145-146]. 
Curcumin can cross the BBB at high levels and it exhibited manifold 
molecular targets. In an in vivo study, human glioma U-87 cells were 
xenografted into athymic mice. Authors confirmed that Curcumin 
was competent enough to subdue glioma angiogenesis via impeding 
Matrix metallopeptidase 9 (MMP-9) and downregulating endothelial 
cell markers (CD31 and CD105 mRNA [146]. Another research work 
of Wu B et al. stated that in U-251 malignant glioblastoma cells, 
when Curcumin was used it induces the arrest of G2/M cell cycle by 
swelling protein kinase 1 (DAPK) [147]. 
CONCLUSION  
Curcumin, a golden drug has been studied widely and still, 
researchers are appraising this compound for its different 
therapeutic uses. Curcumin exhibited a wide range of spectrum 
against numerous types of cancers. Being natural, its efficiency with 
less or no side effects has been evidenced by many researchers in 
several clinical trials also, but low bioavailability and less solubility 
hinder its anticancer activity. To overcome these major issues, 
several approaches such as combination therapy, diverse drug 
delivery modes, synthesis of Curcumin derivatives, chemical 
modification of Curcumin moiety etc. were widely explored by the 
researchers. Still, there are many gaps which have to be plug by 
further research. On the other hand, teething troubles with chemical 
modification and synthesis of Curcumin derivatives like less 
stability, effectiveness, bioavailability, water-solubility, target 
delivery, the requirement of high potency for the treatment etc. 
persists. In general, it has been noticed that to achieve one target; 
there will be a sacrifice of another target. Thus, there is an urgent 
need of focusing research work to enhance bioavailability and 
hydrophilicity of Curcumin, to understand its working mechanism in 
terms of action and reactions. Lack of clinical studies give enough 
opportunity to bring the lab work at the level of clinical trials.  
ABBREVIATION 
A-549-Adenocarcinomic human alveolar basal epithelial cells, AKT-
Protein kinase B (PKB), also known as Akt, is a serine/threonine-
specific protein kinase, Akt/mTOR-Intracellular signalling pathway, 
anti-HCC effect-Anti-hepatocellular carcinoma, AP-1-Activator 
protein-1, AR-Androgen receptor, AsPc-1-Human pancreatic 
adenocarcinoma cell line, Bax/-Bcl-2-associated X protein, Bcl-2/-
Protein family, Bcl-xl-B-cell lymphoma-extra large, BRAF-Human 
gene referred to as proto-oncogene B-Raf and v-Raf murine sarcoma 
viral oncogene homolog B, BxPc-3-Human pancreatic cancer cell 
line, CD105-Endoglin (CD105) is an accessory receptor, CD31-
Platelet endothelial cell adhesion molecule (PECAM-1) also known 
as cluster of differentiation 31, CDK1-Cyclin-dependent kinase 1, 
COX-2–Cyclooxygenase-2, CUR–Curcumin, DiMC-Dimethoxy 
curcumin, DNA-Deoxyribonucleic acid, DU145–Human Prostate 
cancer cell line, EGFR-Epidermal growth factor receptor, ERK-
Extracellular-signal-regulated kinase, FOLFOX-Folinic acid 
(leucovorin) "FOL", Fluorouracil (5-FU) "F", and Oxaliplatin 
(Eloxatin) "EX"., 5-FU–5 Fluorouracil, G/M phase–Cell cycle, GSH-
Glutathione, HA22T/VGH-Human hepatoma-derived cell line, HCT-
116-Human colon cancer cell line, HeLa cell–Human cervical cancer 
cell line, HeLa cells-Henrietta Lacks cervical cancer cells, HER-2-
Human epidermal growth factor receptor 2, HT-29-Human 
Colorectal Adenocarcinoma, K562-First human immortalised 
myelogenous leukemia cell line, LS-174-T-human colon carcinoma 
cell, MAPK-Microtubule associated protein kinase, MAPK-Mitogen-
activated protein kinase, MCF-7-Michigan Cancer Foundation breast 
cancer cell line, MDA-MB 231-M. D. Anderson-Metastasis Breast 
cancer-231, MEK–[acronym MEK derives from MAPK/ERK Kinase 
(Mitogen-activated protein kinase kinase/extracellular-signal-
regulated kinase)], MGC-803-Human gastric carcinoma cell line 
MGC-803, MIA PaCa-2-Human pancreatic cancer cell line, mRNA–
Messenger RNA, NCI-H460-Lung cancer cell line H460of the 60 cell 
lines from National Cancer Institute, NFW–Nanofibre weaving 
Technology, NF-κB-Nuclear factor kappa-light-chain-enhancer of 
activated B cells, nM–Nano Molar, p53-Tumor protein, PANC-1–
Pancreatic Adenocarcinoma cancer cell line, PARP-Poly (ADP-
ribose) polymerase, PC-3-Prostate cancer cell line, PC3-Prostate 
Cancer cell lines, PCa cell lines–Prostate Cancer cell lines, PDT-
Photodynamic therapy, PI3K-Phosphoinositide 3-kinase, ROS–
Reactive Oxygen Species, RTKs–Receptor Tyrosine Kinases, SK-BR-
3-Memorial Sloan–Kettering Cancer Center, STAT3-Signal 
transducer and activator of transcription 3, TE-8-Human 
oesophageal cancer cells, Th2-T Helper Cell Type 2, TNF α-Tumor 
necrosis factor-alpha, VEGF-Vascular endothelial growth factor, 
Wnt1 gene-Proto-oncogene protein Wnt-1 is a protein, ZR-75–
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